Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
156.76
+2.73 (1.77%)
Sep 1, 2026, 4:00 PM EDT - Market closed
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $959.00M in the quarter ending June 30, 2026, with 39.49% growth. This brings the company's revenue in the last twelve months to $3.37B, up 34.42% year-over-year. In the year 2025, Neurocrine Biosciences had annual revenue of $2.86B with 21.45% growth.
Revenue (ttm)
$3.37B
Revenue Growth
+34.42%
P/S Ratio
4.72
Revenue / Employee
$1,686,950
Employees
2,000
Market Cap
15.93B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.86B | 505.20M | 21.45% |
| Dec 31, 2024 | 2.36B | 468.20M | 24.81% |
| Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
| Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
| Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
| Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
| Dec 31, 2019 | 788.10M | 336.90M | 74.67% |
| Dec 31, 2018 | 451.20M | 289.57M | 179.16% |
| Dec 31, 2017 | 161.63M | 146.63M | 977.51% |
| Dec 31, 2016 | 15.00M | -4.77M | -24.12% |
| Dec 31, 2015 | 19.77M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 2.92M | -50.22M | -94.51% |
| Dec 31, 2012 | 53.14M | -24.27M | -31.36% |
| Dec 31, 2011 | 77.41M | 43.91M | 131.08% |
| Dec 31, 2010 | 33.50M | 30.55M | 1,034.47% |
| Dec 31, 2009 | 2.95M | -1.02M | -25.71% |
| Dec 31, 2008 | 3.98M | 2.75M | 224.75% |
| Dec 31, 2007 | 1.22M | -38.01M | -96.88% |
| Dec 31, 2006 | 39.23M | -84.66M | -68.33% |
| Dec 31, 2005 | 123.89M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Viatris | 14.74B |
| Zoetis | 9.53B |
| Elanco Animal Health | 5.02B |
| Dr. Reddy's Laboratories | 3.50B |
| United Therapeutics | 3.15B |
| Amneal Pharmaceuticals | 3.12B |
| Hims & Hers Health | 2.58B |
| Alkermes | 1.67B |
NBIX News
- 16 days ago - Neurocrine announces INECT-PRO Phase 4 open-label study results - TheFly
- 16 days ago - Neurocrine price target lowered to $165 from $190 at Deutsche Bank - TheFly
- 16 days ago - Neurocrine price target lowered to $182 from $196 at Morgan Stanley - TheFly
- 16 days ago - Neurocrine price target lowered to $218 from $221 at Bernstein - TheFly
- 20 days ago - Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia - PRNewsWire
- 20 days ago - Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
- 25 days ago - Neurocrine initiates Phase 1 study of NBIP-‘1968 - TheFly
- 25 days ago - Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist - PRNewsWire